

*Fetal Provider Information Sheet*

*Last Updated: 6/13/19*

*Authors: Angira Patel MD, Ed. Shubhika Srivastava*

## **Atrioventricular Septal Defect (AVSD)**

### Incidence [1]

- 2.4-3.1/10,000 live births, 4-5% of all CHD
- 57-92% prenatal detection rate

Fetal Interventions (None)

Fetal Imaging Predictors of Postnatal Management/Outcome

- Key predictor of outcome is balance of atrioventricular valve
  - RV/LV EDD ration between 2 and 4 SDs for gestational age suggests a borderline LV
  - Presence of an apex-forming LV is a predictor of biventricular repair

### Prognosis [6, 7,8]

- Main prognostic factor based on associated genetic and extracardiac abnormalities and balance of atrioventricular valve
  - Postnatal TTE: Calculated AVVI  $< 0.67$  + large VSD, recommend single ventricle approach
  - Postnatal TTE: To help determine unbalanced or not: AVVI (atrioventricular valve index)  $\leq 0.4$  (right dominant) or  $\geq 0.6$  (left dominant)
- Low operative mortalities for balanced AVSD: 2.2%
- Higher mortality in cases with associated malformations (with the exception of T21)
- Most common reason for reoperation: left AVV regurgitation  $>$  subaortic stenosis  $>$  residual VSD  $>$  late onset CHB

### **Mortality, Risk and Indication for Reoperation in Balanced AVSD** [9, 10, 11]

- Quoted reoperation rates from 10-25%
- Mortality and freedom from reoperation vary based on surgical era, and years of long-term follow-up

**DISCLAIMER:** All information provided is for educational and informational purposes only and is not intended to be a substitute for professional medical advice, diagnosis, or treatment. FHS does not recommend or endorse any specific treatments, tests, results, physicians, centers, products, procedures, opinions, or other information that may be included in this summary. Further, there are no representations or warranties regarding errors, omissions, completeness or accuracy of the information provided.

<b>Years Evaluated</b>	<b>Indications for Reoperation</b>	<b>Freedom from reoperation</b>	<b>Survival</b>
1972-2007 [9]	LAVV regurgitation Subaortic stenosis LAVV stenosis, Residual ASD PA stenosis Aortic coarctation	63% at 5 yr 48% at 10 yr 42% at 15 yr	91% at 5 yr 91% at 10 year 86% at 15 year
1974-2000 [10]	LAVV regurgitation LVOTO	88% at 10 yr 83% at 20 yr 78% at 30 yr	85% at 10 yr 82% at 20 yr 71% at 30 yr
1975-2006 [11]	Residual ASD LAVV regurgitation	96% at 1 yr 89% at 5 yr 82% at 15 yr	91% at 1 yr 91% at 5 yr 89% at 15 yr

#### Associated Problems [1, 3, 4, 5]

- Chromosomal abnormalities, syndromes, extracardiac findings
  - 17-50% of Trisomy 21 have AVSD
  - Abnormal karyotype in 48-58% of those diagnosed with AVSD
- Associated defects:
  - Subaortic stenosis: due to subaortic shelf or fibromuscular tunnel, also evaluate for aortic valve hypoplasia and coarctation of aorta
  - Tetralogy of Fallot: 5% in patients with AVSD, more common in those with Trisomy 21
  - Atrial isomerism: right > left; If right, more likely univentricular heart with common atrium; If left, more likely biventricular heart and CHB common
  - Ventricular hypoplasia
    - Balanced vs. unbalanced will determine biventricular or univentricular repair
- AVV regurgitation – poorer prognosis, contributes to development of hydrops in utero

**DISCLAIMER:** All information provided is for educational and informational purposes only and is not intended to be a substitute for professional medical advice, diagnosis, or treatment. FHS does not recommend or endorse any specific treatments, tests, results, physicians, centers, products, procedures, opinions, or other information that may be included in this summary. Further, there are no representations or warranties regarding errors, omissions, completeness or accuracy of the information provided.



*Fetal Provider Information Sheet*

*Last Updated: 6/13/19*

*Authors: Angira Patel MD, Ed. Shubhika Srivastava*

References:

1. Craig, B. *Heart* 2006;92:1879–1885
2. Muresan D, et al. *Med Ultrason* 2016, Vol. 18, no. 4, 500-507
3. Pitkanen, *Am Heart J* 2006; 152 (1) p.163
4. Cohen, *JACC*, 1996;28: 1017-23
5. Jegatheeswaran, *Circulation* 2010; 122: S209-S215
6. Jacobs, *Ann Thorac Surg*, 2011; 92 (6): 2184-91
7. Fesslova, *Cardiol Young*, 2002; 12 (1): 18-26
8. Beaton, *JASE*. 2013 Feb;26 (2):206-18
9. Stulak, et al. *Ann Thorac Surg*. 2009 Jun;87(6):1872-7
10. Ginde, et al. *J Thorac Cardiovasc Surg*. 2015 Aug;150(2):369-74
11. Hooenkerk, et. Al. *Ann Thorac Surg*. 2010 Nov;90(5):1554-61

**DISCLAIMER:** All information provided is for educational and informational purposes only and is not intended to be a substitute for professional medical advice, diagnosis, or treatment. FHS does not recommend or endorse any specific treatments, tests, results, physicians, centers, products, procedures, opinions, or other information that may be included in this summary. Further, there are no representations or warranties regarding errors, omissions, completeness or accuracy of the information provided.